Tax withholding sale by Voyager (VYGR) COO Robin Swartz

Rhea-AI Filing Summary

Voyager Therapeutics COO & CBO Robin Swartz reported an automatic tax-related sale of 6,458 common shares. On February 24, 2026, shares were sold in an open-market transaction at a weighted average price of $3.77 per share.

The sale was executed under a durable automatic sale instruction adopted on May 12, 2025 to cover tax withholding obligations from restricted stock units that vested on February 21, 2026, and is described as non-discretionary. After this sale, Swartz directly held 199,738 Voyager Therapeutics shares.

Insider Trade Summary

Net Seller: 6,458 shares ($24,347)

Net Sell 1 txn

Insider Swartz Robin

Role COO & CBO

Sold 6,458 shs ($24K)

Type	Security	Shares	Price	Value
Sale	Common Stock	6,458	$3.77	$24K

Holdings After Transaction: Common Stock — 199,738 shares (Direct)

Footnotes (1)

1. Represents shares of common stock of Voyager Therapeutics, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on May 12, 2025, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 21, 2026. The sales do not represent a discretionary trade by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.61 to $3.86, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Swartz Robin

(Last) (First) (Middle)

C/O VOYAGER THERAPEUTICS, INC.

75 HAYDEN AVENUE

(Street)

LEXINGTON MA 02421

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Voyager Therapeutics, Inc. [ VYGR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	COO & CBO

3. Date of Earliest Transaction (Month/Day/Year)
02/24/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/24/2026		S(1)		6,458(1)	D	$3.77(2)	199,738	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of common stock of Voyager Therapeutics, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on May 12, 2025, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 21, 2026. The sales do not represent a discretionary trade by the reporting person.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.61 to $3.86, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

	/s/ Gregory L. Shiferman, as Attorney-in-Fact for Robin Swartz	02/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Voyager Therapeutics (VYGR) report for Robin Swartz?

Voyager Therapeutics reported that COO & CBO Robin Swartz sold 6,458 shares of common stock. The transaction occurred on February 24, 2026, and was executed as an automatic sale to cover tax withholding obligations tied to recently vested restricted stock units.

At what price did Robin Swartz’s Voyager Therapeutics (VYGR) shares sell?

The filing states a weighted average sale price of $3.77 per share. Shares were sold in multiple trades within a range from $3.61 to $3.86, and the company notes it can provide detailed per-trade pricing information upon request to interested parties.

Was Robin Swartz’s Voyager Therapeutics (VYGR) share sale discretionary?

No, the sale is described as non-discretionary. It was made under a durable automatic sale instruction adopted on May 12, 2025, specifically to implement a sell-to-cover election for tax withholding tied to restricted stock units vesting on February 21, 2026.

How many Voyager Therapeutics (VYGR) shares does Robin Swartz hold after the sale?

After selling 6,458 shares, Robin Swartz directly holds 199,738 shares of Voyager Therapeutics common stock. This post-transaction balance reflects only the shares reported in the Form 4 and does not include any unvested equity awards or derivative securities not mentioned.

Why did Robin Swartz sell Voyager Therapeutics (VYGR) shares in this Form 4 filing?

The sale was to satisfy tax withholding obligations from restricted stock units that vested on February 21, 2026. The filing explains that the transaction followed a durable automatic sale instruction implementing a sell-to-cover election, rather than a discretionary decision to sell shares.

What does the weighted average price disclosure mean in the Voyager Therapeutics (VYGR) Form 4?

The Form 4 reports a weighted average price of $3.77 because shares were sold in multiple trades between $3.61 and $3.86. The reporting person commits to provide detailed breakdowns of the number of shares sold at each specific price within that range upon request.